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In October 2007, enrolments into and vaccinations for a South African 
phase IIb HIV vaccine trial (HVTN 503, or Phambili) were suspended, 
based on negative results from a companion study in the Americas 
(HVTN 502 or STEP). STEP results showed that the vaccine did not 
prevent HIV acquisition or ameliorate disease, and in fact indicated a 
trend towards increased infection in a subgroup of vaccinees. 
Although, as far as the authors are aware, no claim for compensation 
was made by participants in the South African Phambili trial, this article 
explores the complexities that would have faced participants had they 
attempted such a claim in terms of the Department of Health (DoH) 
Good Clinical Practice (GCP) guidelines of 2006.1  Using the Phambili 
trial as a case study, we are able to identify certain limitations of DoH 
GCP (2006) that might apply across a range of clinical trials. 
The South African ethical-legal framework 
South Africa has a comprehensive ethical-legal framework for 
regulating clinical trials.2 The framework creates a system of 
regulation through:
• a number of institutions that set the policy agenda, establish 
norms and standards and review individual studies
• ethical guidelines and, to a lesser extent, laws, which establish 
substantive and procedural norms for conducting research 
• monitoring and enforcement mechanisms administered by 
statutory institutions such as the Medicines Control Council (MCC), 
research ethics committees (RECs), the National Health Research 
Ethics Council (NHREC), professional councils and the courts. 
The framework deals with research-related injuries expressly 
through the DoH GCP (2006) guidelines. These guidelines set out the 
circumstances and requirements that must be met for participants to 
claim financial compensation for such injuries. 
Delictual claims in South Africa are not the subject of this article, 
but harm from a research-related injury could also be classified as 
a delict. Participants are not precluded from claiming damages in 
terms of the civil law, though such claims would require plaintiffs to 
demonstrate negligence. 
The STEP and Phambili HIV vaccine trials
Both the STEP and Phambili trials were phase IIb, randomised, 
double-blind, placebo-controlled HIV vaccine trials of the Merck 
adenovirus serotype 5 (Ad5) vector-based vaccine. Ad5 is a strain of 
the common cold used to deliver HIV genes made in a laboratory.  
The STEP HIV vaccine trial was designed to evaluate the safety and 
efficacy of the Merck Ad5 vaccine. It enrolled 3 000 HIV-negative 
volunteers from different geographical areas in the Americas, 
Australia and the Caribbean who each received three doses of either 
the vaccine or a placebo. The vaccine contained a mix of Ad5 vectors 
carrying one of three different HIV genes – gag, pol, or nef. The inserts 
were from HIV clade B, matching the predominant clade circulating 
in the areas where the trials took place.3 The trial was co-sponsored 
by the National Institute of Allergy and Infectious Diseases (NIAID), 
and the pharmaceutical company Merck & Co., Inc., which developed 
and supplied the candidate vaccine.4
Immunisations were stopped on 21 September 2007, after an interim 
analysis by the data safety monitoring board (DSMB) determined 
that the vaccine would not meet its efficacy endpoints. Subsequent 
analysis indicated a trend toward more HIV infections among a sub-
set of vaccinees than among placebo recipients. 
The HVTN 503 (Phambili) trial of the same candidate vaccine was 
conducted in South Africa and funded by grants from the NIAID to 
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the HIV Vaccine Trials Network, as well as by Merck & Co., Inc. The 
South African AIDS Vaccine Initiative (SAAVI) provided support to the 
clinical trial sites.5 This companion study aimed to evaluate the safety 
and efficacy of the Merck vaccine and enrolled 801 participants 
prior to the suspension of enrolments.4 The Phambili study tested 
the vaccine in high-risk men and women in South Africa, and was 
intended as a test of the vaccine’s potential for cross-clade protection. 
Following the interim findings from the STEP study, immunisations 
and enrolments in the Phambili study were paused to allow for further 
analysis of the STEP data. Based on the additional review of this data, 
a separate, independent DSMB for the Phambili trial concluded 
that there was no basis for anticipating more favourable results in 
the South African clinical trial. Therefore, the Phambili oversight 
committee permanently suspended immunisations and enrolment 
in the study.4 This DSMB also noticed a trend towards increased HIV 
susceptibility in volunteers who had received the vaccine, although 
this was not statistically significant. 
Increased susceptibility to HIV infection in 
the STEP and Phambili trials
There appears to be debate in the literature regarding the factors, or 
interaction between factors, that put STEP vaccinees at increased risk 
of HIV infection compared with unvaccinated volunteers. 
Initial analyses of the STEP data showed a trend towards increased risk 
of HIV infection in Ad5-seropositive men and uncircumcised men.6 
Further analyses only confirm that uncircumcised men who received 
the vaccine were at increased risk of HIV infection, but not that this 
risk increased for Ad5-seropositive participants who received it.7 
Similarly it was argued that, while being an uncircumcised vaccinee 
was a risk factor on its own, Ad5 seropositivity is only a risk factor 
in conjunction with being uncircumcised and that ‘pre-existing 
immunity to Ad5, in and of itself … does not appear to be associated 
with an increased risk of HIV infection.’8 
Multivariate analyses have shown that these risk factors are not 
confounded by other demographic and risk variables measured at 
baseline. However, this does not rule out confounding variables that 
have not yet been measured, such as host genetic factors.9 In summary, 
it appears that all uncircumcised vaccinees were at increased risk 
for HIV infection, and that Ad5-seropositive vaccinees were not at 
increased risk for HIV unless they were also uncircumcised. 
There has also been debate about the mechanism via which 
enhanced susceptibility among STEP vaccinees might have occurred. 
One explanation is that repeated administration of the Ad5 vector in 
uncircumcised men, or men who were both uncircumcised and Ad5-
seropositive, ‘might cause an as yet undefined effect on the immune 
response that leads to an increase in HIV acquisition’.8 
Another hypothesis for increased susceptibility among uncircumcised 
men is that vaccine-induced T-cell responses rapidly travel from 
the injection site to the mucosal tissue of the foreskin, creating a 
permissible environment for HIV infection in the early months after 
vaccination.8 Furthermore, it was speculated that ‘participants with 
high baseline Ad5 titres may generate an altered local immune 
response to rAd5 vaccine administration, and this may further 
enhance HIV infection of target cells in the genital tract tissue’.8
For the Phambili trial, HIV incidence was similar in the vaccine and 
placebo groups (34 HIV infections in vaccinees and 28 in placebo-
recipients) and 58% of participants acquiring infection were 
female.5 The authors found no evidence of increased risk of HIV 
infection in vaccinated participants compared with participants 
receiving the placebo. In addition, they found no such evidence 
in Ad5-seropositive participants, nor in uncircumcised men.5 
Therefore, in this trial, antibody titres against Ad5 did not correlate 
with increased HIV infection.7 Furthermore, circumcision status 
did not predict infection or modify the effect of treatment.5 The 
authors stated that early cessation of vaccination and unblinding of 
participants made it difficult to draw conclusions about the efficacy 
of the vaccine.
Compensation claims under DoH GCP 
(2006) guidelines
The DoH GCP (2006) guidelines require researchers and sponsors 
of clinical trials to take out comprehensive insurance against injury 
and damage that participants may experience as a result of the trials. 
These guidelines give direction on the payment of compensation 
(from the insurers) for research-related injury. The guidelines also 
provide that participants may have a claim if it can be shown that 
a trial product or procedure was administered that caused serious 
bodily injury of an enduring character that would not have occurred 
but for participation in the trial. 
Accordingly, 3 requirements should be satisfied:
• conduct, i.e. an act or omission on behalf of the researchers or 
sponsors leading to a harm 
• harm, i.e. serious bodily injury of an enduring nature arising from a 
trial product or procedure (there is no compensation for temporary 
pain or discomfort or for less serious or curable complaints) 
• causation, i.e. that the harm would not have occurred but 
for trial participation, and that there is an unbroken link 
between the conduct and the harm caused. Participants are 
only required to prove that such harm occurred on the balance 
of probabilities.
Claims for compensation should be made to the sponsor via the 
investigator. 
The DoH GCP (2006) guidelines take a strict liability approach by 
providing that there is no need to prove negligence on the part of 
researchers or sponsors. The guidelines specify that only damages 
for bodily injury may be claimed. It is submitted that this means 
participants could only claim for damages relating to their bodily 
injury such as medical expenses, pain and suffering, loss of income, 
shortened life expectancy, and incidental costs.10 
Participants may not profit from the wrongful acts of others, 
and therefore damages must aim at putting them in the same 
position they would have been in had they not suffered the 
wrong. Furthermore the quantum should be proportionate to 
the nature, severity and persistence of the injury, and should be 
consistent with the quantum of damages commonly awarded 
for similar injuries in terms of South African law on delict. Finally, 
the guidelines provide that where participants have contributed 
to their own harm, this should be taken into account (so-called 
‘contributory negligence’). 
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Application to the Phambili case
While we argue that conduct exists that leads to potential harm, in 
the form of the act of administering the experimental vaccine to 
participants, demonstrating other elements in this case is a complex 
exercise. Some might argue that Phambili vaccine recipients 
experienced serious bodily injury in that they were at risk of 
enhanced susceptibility to HIV. However, it might be counter-argued 
that the trial data do not support this view as there are no statistically 
significant differences in HIV infections between vaccine recipients 
and placebo recipients. Even if this view was supported by data, 
enhancement may not endure (G Gray, personal communication) 
and therefore the injury may not be of an enduring nature as required 
by GCP (2006). It could also be argued that vaccine-recipients who 
experienced enhancement, and subsequently acquired HIV infection, 
suffered serious bodily harm of an enduring nature, satisfying the 
requirements in GCP (2006), and furthermore that a causal link 
existed between the conduct and the serious bodily injury, because 
‘but for’ vaccination the enhancement would not have occurred
However, it might be counter-argued that trial data do not support 
this conclusion, as the difference in HIV infections between vaccine 
and placebo groups was not statistically significant (in other words, 
there are no reasons to believe that the results observed are not due to 
chance). Damages would be calculated according to costs incurred for 
participants’ actual ‘bodily injury’ in the categories described above. It 
is possible that sponsors might argue for a reduction in damages based 
on ‘contributory negligence’, i.e., that trial participants who became 
HIV-infected contributed to their own harm by not implementing risk-
reduction measures provided in the trial. 
It is important to note that the issue of financial compensation 
for research-related injury should be viewed as distinct from two 
other ethical responsibilities in such trials. First, it is distinct from 
researchers’ responsibility to provide a high standard of preventative 
measures to prevent participants contracting HIV.11 In the Phambili 
trial, these measures included the provision of counselling, 
condom promotion, treatment for sexually transmitted infections, 
the option of free medical male circumcision, and post-exposure 
prophylaxis for both sexual assault and high-risk sexual encounters.5 
Second, the issue of compensation is also distinct from researchers’ 
responsibility to ensure that HIV-related care needs identified in trials 
are addressed.12-14 In the Phambili trial these steps included intensive 
counselling, monitoring of CD4 and viral loads, and assisted referrals 
for care and treatment including anti-retroviral treatment (ART).5 
Critique of the DoH GCP (2006) guidelines 
Using the Phambili trial as a case study reveals a number of 
shortcomings of the DoH GCP (2006) guidelines. Key concerns that 
emerge include: 
• The DoH GCP (2006) guidelines limit claims for harm to those of an 
‘enduring’ nature. This is a narrow approach insofar as many harms 
that are serious might not endure, but this does not detract from 
their status as harms. The best time to take durability of harm in to 
account may be when determining quantum of damages. 
• The guidelines exclude claims that are not for ‘bodily’ injury, which is 
out of step with modern approaches to providing damages for both 
physical and psychological harm.10 Our courts have consistently held 
that claims for psychological damages may be made (RAF v Sauls 
2002 (2) SA 55(SCA)). Furthermore, they have dismissed arguments 
that such an approach opens the floodgates to thousands of claims 
by holding that the normal standards of delictual liability and onus 
of proof will ensure the parameters of liability are carefully drawn.15 
In the Phambili trial, knowledge of enhanced susceptibility to HIV 
infection may have caused participants anxiety or stress, especially 
for participants with knowledge of increased risk who were unable 
to implement risk-mitigation steps because they were unable to 
negotiate safer sex with their partners. 
The guidelines state that claims should be made to the sponsor via the 
investigator. We argue that this requires participants to make their first 
approach to parties who may not be neutral in relation to the pursuit of 
a claim. It also provides no institutional support to such claimants, e.g. 
by involving RECs whose mandate is to protect participants’ rights and 
welfare. In addition, this stipulation provides no process for appeal or 
review, thus forcing unsuccessful applicants to rely on administrative 
or civil law if their claims fail. 
Conclusion
Compensation for research-related harm is an important protection 
for trial participants,16 and it is commendable that South African 
authorities require investigators to obtain insurance to cover the cost 
of research-related injury.17 We submit that the South African DoH 
(GCP) 2006 guidelines could be strengthened by addressing certain 
substantive and procedural limitations. We recommend that these 
guidelines be amended to ensure:
• the term ‘harm’ is more broadly defined 
• more detail is provided on a range of possible damages that may 
be claimed 
• RECs are recommended as a party more appropriately placed 
to assist participants who have queries about compensation for 
research-related injury.
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